Agenda/Faculty: COURSE CHAIR
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI
Chief of Cardiology
VA Boston Healthcare System
Director, Integrated Interventional Cardiovascular Program
Brigham and Women's Hospital & VA Boston Healthcare System
Associate Professor of Medicine, Harvard Medical School
Senior Investigator, TIMI Study Group
Boston, Massachusetts Disclosures:
• Contracted Research: AstraZeneca, Bristol Myers Squibb, Eisai, Sanofi Aventis, The Medicines Company FACULTY
Christopher P. Cannon, MD
Senior Investigator, TIMI Study Group
Cardiovascular Division, Brigham and Women's Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts Disclosures:
• Grant/Research support: Accumetrics, AstraZeneca, GlaxoSmithKline, Intekrin Therapeutics, Merck, Takeda
• Advisory Board: Alnylam, Bristol Myers Squibb/Sanofi, Novartis
• Honorarium for Development of Independent Educational Symposia: AstraZeneca, Pfizer
• Clinical Advisor/Equity: Automedics Medical Systems
E. Magnus Ohman, MD, FRCPI, FESC, FACC, FSCAI
Professor of Medicine
Associate Director Duke Heart Center - Cardiology Clinics
Director, Program for Advanced Coronary Disease
Duke Clinical Research Institute
Duke University Medical Center
Durham, North Carolina Disclosures:
• Consulting Fees: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Gilead Sciences, Liposcience, Merck, Sanofi Aventis, The Medicines Company, WebMD
Contracted Research: Daiichi Sankyo, Eli Lilly & Company, Maquet
Fees for Non-CME Services: Pozen, Inc. Philippe Gabriel Steg, MD, FACC
Professor of Cardiology
Director, Coronary Care Unit
Hospital Bichat-Claude Bernard
Service de Cardiologie
Paris, France Disclosures:
• Grant/Research support (all paid to institution, not individual): Servier
• Consulting/Advisory Board: Ablynx, Astellas, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo-Lilly, Eisai, GlaxoSmithKline, Medtronic, Merck Sharp & Dohme, Pfizer, Roche, Sanofi Aventis, Servier, The Medicines Company
• Stockholding and Co-Founder: Aterovax External Reviewer reports the following
relationship(s):
Ronald A. Codario, MD, FACP (Employee of Vindico Medical Education)
• No relevant financial relationship to disclose. Vindico Medical Education staff report the following relationship(s):
• No relevant financial relationships to disclose Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance. Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears on this page and the next page. The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
|
Program Title: Acute Coronary Syndrome: Options for Primary & Secondary Prevention  Issued: 06/20/2011 CME Term of Approval: 06/19/2012 Estimated Time to Complete Activity: 1.5 hours Statement of Need: Achieving the best outcomes for patients with acute coronary syndromes requires staying current with the latest treatment guidelines from the American College of Cardiology and American Heart Association, and identifying patients who face additional risk factors and may require more individualized regimens. In this activity, leading clinicians will offer practical recommendations based on the latest guidelines, while discussing treatment options for patients who may not respond to some antiplatelet therapies. Target Audience:
The intended audience for this activity is cardiologists and other healthcare professionals involved in the treatment of patients with acute coronary syndrome. Learning Objectives: Upon completion of this activity, participants should be able to:  Implement ACC/AHA guideline recommendations for the management of patients with acute coronary syndromes. Describe the influence of genetic variations in enzymes or potential drug interactions involving antiplatelet responsiveness, degree of platelet inhibition, and protection from cardiovascular events. Apply updated ACC/AHA guidelines on the assessment and management of antiplatelet therapy resistance in patients with ACS. Evaluate new options for pharmacogenetic and platelet function testing into clinical decision-making for patients with ACS.
CME Accreditation Statement:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Credit Designation:
Vindico Medical Education designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclaimer:
The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Method of Participation:
To participate in this CME activity, you must read the objectives, answer the pretest questions, read the articles, complete the CME posttest, and complete and return the registration form and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™.
Sponsored by:
This activity is cosponsored by Vindico Medical Education and the American College of Cardiology Foundation. Supported by:
This CME activity is supported by an educational grant from Merck & Co., Inc.
 |